This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sterling-Levis, K. Articles by Tobias, V. Search for Related Content PubMed PubMed Citation Articles by Sterling-Levis, K. Articles by Tobias, V.

Heterotransplantation of Early B-Lineage Acute Lymphoblastic Leukemia Using a Solubilized Attachment Matrix (Matrigel)¹

The Children's Leukaemia and Cancer Research Centre [K. S-L., L. W., A. E. T., C. G., S. M. P.] and Departments of Haematology-Oncology [L. W.] and Anatomical Pathology [V. T.], The Prince of Wales Children's Hospital, Randwick, Sydney, New South Wales, 2031 Australia

Maintenance of long term culture and conventional xenografting of early B-lineage acute lymphoblastic leukemia cells is most difficult. Matrigel, a solubilized attachment matrix shown to aid growth of anchorage dependent solid tumors, was studied in heterotransplantation. Material for xenografting was derived from 5 patient bone marrow aspirates and 5 cell lines previously established and maintained by intraocular inoculation in nude mice. Specimens were injected by 3 methods: intraocular (n = 397); S.C. in medium (n = 78); and S.C. in medium supplemented by Matrigel (n = 69). With intraocular injection, 6 of 10 cell sources grew with respective ingraftment rates of 29–76%. Using the conventional S.C. method, no tumors resulted. The addition of Matrigel produced S.C. ingraftment from 8 of 10 cell sources (ingraftment rate, 50–100%). Immunophenotype, histopathology, and karyotype of the cells derived after Matrigel dependent ingraftment correlated with the cells of origin. It is concluded that Matrigel enables establishment and maintenance of early B-lineage acute lymphoblastic leukemia cell growth in a S.C. xenograft model.

¹ This work was supported by the Children's Leukaemia and Cancer Foundation, Sydney, Australia.

² To whom requests for reprints should be addressed.

Received 11/30/92. Accepted 2/ 1/93.

This article has been cited by other articles:

				A. Lamikanra, Z.-K. Pan, S. N. Isaacs, T.-C. Wu, and Y. Paterson Regression of Established Human Papillomavirus Type 16 (HPV-16) Immortalized Tumors In Vivo by Vaccinia Viruses Expressing Different Forms of HPV-16 E7 Correlates with Enhanced CD8+ T-Cell Responses That Home to the Tumor Site J. Virol., October 15, 2001; 75(20): 9654 - 9664. [Abstract] [Full Text] [PDF]

				A. E. Evans, K. D. Kisselbach, D. J. Yamashiro, N. Ikegaki, A. M. Camoratto, C. A. Dionne, and G. M. Brodeur Antitumor Activity of CEP-751 (KT-6587) on Human Neuroblastoma and Medulloblastoma Xenografts Clin. Cancer Res., November 1, 1999; 5(11): 3594 - 3602. [Abstract] [Full Text] [PDF]